XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA and XyloCor intends to commence clinical trials in early 2020.
XC002 is the second XyloCor program and it is being developed for regeneration of cardiac tissue in patients who have poorly functioning hearts as a result of past heart attacks and resulting heart failure. XC002 has transformed non-functioning cardiac cells into function cardiac cells in animal models.